Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars M Ittner

Showing results (11-20 of 161) with videos related to

Pageof 17
Sort By:
British Journal of Pharmacology|November 3, 2011
Tau-targeted treatment strategies in Alzheimer's diseaseJürgen Götz, Arne Ittner, Lars M Ittner
The European Journal of Neuroscience|July 30, 2008
Divergent phosphorylation pattern of tau in P301L tau transgenic miceNatasha Deters, Lars M Ittner, Jürgen Götz
Journal of Neurochemistry|June 22, 2006
Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?Jürgen Götz, Lars M Ittner, Stefan Kins
The Medical Journal of Australia|October 4, 2006
Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?Jürgen Götz, Lars M Ittner, Nicole Schonrock
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|October 17, 2006
DiGeorge syndrome and pharyngeal apparatus developmentHeiko Wurdak, Lars M Ittner, Lukas Sommer
Journal of Labelled Compounds & Radiopharmaceuticals|April 1, 2023
Peptides for trans-blood-brain barrier deliveryReuben Blades, Lars M Ittner, Ole Tietz
Journal of Medicinal Chemistry|January 13, 2009
The translocator protein (18 kDa): central nervous system disease and drug designAlana M Scarf, Lars M Ittner, Michael Kassiou
The Journal of Biological Chemistry|June 4, 2009
Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer diseaseLars M Ittner, Yazi D Ke, Jürgen Götz
Expert Review of Neurotherapeutics|March 15, 2014
The translocator protein as a drug target in Alzheimer's diseaseSook W Chua, Michael Kassiou, Lars M Ittner
British Journal of Pharmacology|March 1, 2019
Adeno-associated virus-based Alzheimer's disease mouse models and potential new therapeutic avenuesLars M Ittner, Matthias Klugmann, Yazi D Ke
Pageof 17

Showing results (11-20 of 161) with videos related to

Sort By:
Pageof 17
British Journal of Pharmacology|November 3, 2011
Tau-targeted treatment strategies in Alzheimer's diseaseJürgen Götz, Arne Ittner, Lars M Ittner
The European Journal of Neuroscience|July 30, 2008
Divergent phosphorylation pattern of tau in P301L tau transgenic miceNatasha Deters, Lars M Ittner, Jürgen Götz
Journal of Neurochemistry|June 22, 2006
Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?Jürgen Götz, Lars M Ittner, Stefan Kins
The Medical Journal of Australia|October 4, 2006
Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?Jürgen Götz, Lars M Ittner, Nicole Schonrock
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|October 17, 2006
DiGeorge syndrome and pharyngeal apparatus developmentHeiko Wurdak, Lars M Ittner, Lukas Sommer
Journal of Labelled Compounds & Radiopharmaceuticals|April 1, 2023
Peptides for trans-blood-brain barrier deliveryReuben Blades, Lars M Ittner, Ole Tietz
Journal of Medicinal Chemistry|January 13, 2009
The translocator protein (18 kDa): central nervous system disease and drug designAlana M Scarf, Lars M Ittner, Michael Kassiou
The Journal of Biological Chemistry|June 4, 2009
Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer diseaseLars M Ittner, Yazi D Ke, Jürgen Götz
Expert Review of Neurotherapeutics|March 15, 2014
The translocator protein as a drug target in Alzheimer's diseaseSook W Chua, Michael Kassiou, Lars M Ittner
British Journal of Pharmacology|March 1, 2019
Adeno-associated virus-based Alzheimer's disease mouse models and potential new therapeutic avenuesLars M Ittner, Matthias Klugmann, Yazi D Ke
Pageof 17